While the HRS annual meeting is cancelled, the society has created a resource page to help its members in the fight against COVID-19 at https://www.hrsonline.org/COVID19-Challenges-Solutions. #HRS #COVID19 #coronavirus #SARScov2
Dave Fornell, Editor
April 01, 2020
Heart Rhythm Society Cancels 2020 Meeting Due to COVID-19
April 1, 2020 — Due to the continued global escalation of the novel coronavirus (COVID-19, SARS-CoV-2), the Heart…
Read More
William O’Neill, M.D., Henry Ford Hospital, speaking at the announcement of the creation of the Cardiogenic Shock Initiative in 2016. O'Neill asked the same partner hospitals in the Detroit area to pool resources to create a COVID-19 study group to help speed the gathering of data in COVID-19 drug trials.
March 31, 2020
Cardiologists Head COVID-19 Trial Collaboration in Detroit Area Hospitals
March 31, 2020 — Four metropolitan Detroit hospital systems and a leading research university announced a collaboration…
Read More
March 30, 2020
E-Cigarettes More Effective Than Counseling for Smoking Cessation
March 30, 2020 — Smokers who received smoking cessation counseling and used electronic cigarettes (e-cigarettes)…
Read More
Closing access to the radial artery after harvesting a section of the artery for a coronary artery bypass graft (CABG). Photo by Getty Images. #ACC20 #ACC2020
March 30, 2020
Radial Artery Versus Saphenous Vein For Coronary Bypass Surgery Long Term Follow-up
March 30, 2020 — Patients undergoing coronary bypass graft (CAGB) surgery lived longer and had better outcomes when…
Read More
The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus
March 30, 2020
Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials in Response to Hospitals' COVID-19 Focus
March 30, 2020 — Edwards Lifesciences Corp. announced it is temporarily pausing new enrollments in its active pivotal…
Read More
AHA, ACC, HRS, SCAI and other medical societies call for federal government to do what is needed to get medical supplies to front-line clinicians fighting COVID-19. #COVID19 #SARScov2 #Coronavirus
March 30, 2020
Healthcare Societies Issue Urgent Call for Federal Action to Address COVID-19 Medical Equipment Shortages
March 30, 2020 — A group of 13 U.S. medical societies sent an open letter to Congress appealing to them to do what is…
Read More
Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR
March 30, 2020
TAVR Non-Inferior to Surgery in U.K. Review of Surgery vs. TAVR
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) did…
Read More
PARTNER 3 trial shows positive results for Sapien 3 in low-risk surgical patients. #ACC20 #ACC2020 #Sapien3 #TAVR
March 30, 2020
TAVR Equivalent to Surgery at Two Years in Low-Risk Patients
March 30, 2020 — Low-risk patients undergoing transcatheter aortic valve repair (TAVR) at two years did just as well…
Read More
March 29, 2020
U.S. TAVR Outcomes Need Improvement Based on TVT Registry Analysis
March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing…
Read More
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio
March 29, 2020
Vericiguat Improves Outcomes in Patients with Worsening Heart Failure
March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational…
Read More
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020
Dave Fornell, Editor
March 29, 2020
TAVR Shows Favorable Safety in Patients with Bicuspid Valve
March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve…
Read More
POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
March 29, 2020
POPULAR TAVR Shows Oral Anticoagulants Alone in AF Patients Reduces Bleeding Post TAVR
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing…
Read More
Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020
Dave Fornell, Editor
March 28, 2020
Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials
March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran…
Read More
Find more news from ACC 2020.Women carry heavier burden of chest pain, but less artery narrowing according to data in a substudy of the ISCHEMIA Trial. #ACC20 #ACC2020 #ISCHEMIA
March 28, 2020
Sex Differences in Stress Test and CCTA Findings and Symptoms in the Ischemia Trial
March 28, 2020 — Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia)…
Read More
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis. #ACC20 #ACC2020
March 28, 2020
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis
March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of…
Read More
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020
March 28, 2020
Antiplatelet Genetic Testing Missed Goal to Cut Cardiovascular Events in Half 
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to…
Read More
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20
March 28, 2020
Rivaroxaban Reduces Risks in Peripheral Artery Disease Post-Intervention 
March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with…
Read More
March 27, 2020
ESC and Other Societies Creates a COVID-19 Resource Pages for Cardiology
March 27, 2020 — The European Society of Cardiology (ESC) has created a novel coronavirus resource page with…
Read More
Italian Cardiologist Maurizio Galderisi Died From COVID-19, #coronavirus #COVID19
March 27, 2020
Italian Cardiologist Maurizio Galderisi Died From COVID-19
March 27, 2020 — In Italy today, novel coronavirus (COVID-19) claimed the life of well known cardiologist Maurizio…
Read More
The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  
March 25, 2020
First Human Use of Transcatheter Duo Tricuspid Valve Announced in Ireland
  March 25, 2020 — CroiValve announced the successful first human use of its Duo Tricuspid Coaptation Valve technology…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now